Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study

• Published in: European journal of obstetrics & gynecology and reproductive biology 2002-07, Vol.103 (2), p.140-145
• Main Authors: El-Nemr, A., Bhide, M., Khalifa, Y., Al-Mizyen, E., Gillott, C., Lower, A.M., Al-Shawaf, T., Grudzinskas, J.G.
• Format: Article
• Language: English
• Subjects: Administration, Intranasal; Adult; Biological and medical sciences; Birth control; Buserelin - administration & dosage; Buserelin - adverse effects; Controlled ovarian hyperstimulation; Embryo Transfer; Female; Fertility Agents, Female - administration & dosage; Fertility Agents, Female - adverse effects; Fertilization in Vitro; Gonadotrophin-releasing hormone; Gonadotropin-Releasing Hormone - analogs & derivatives; Gynecology. Andrology. Obstetrics; Humans; IVF; Leuprolide - administration & dosage; Leuprolide - adverse effects; Medical sciences; Menotropins - therapeutic use; Nafarelin - administration & dosage; Nafarelin - adverse effects; Oocytes - physiology; Ovulation Induction - methods; Pregnancy; Pregnancy Rate; Prospective Studies; Sterility. Assisted procreation; Treatment Outcome
• ISSN: 0301-2115; 1872-7654
• DOI: 10.1016/S0301-2115(01)00297-4

The efficacy and safety of short acting buserelin and nafarelin intranasal spray were compared to long acting leuprorelin depot intramuscular or subcutaneous injection in this prospective study of 157 women undergoing controlled ovarian hyperstimulation (COH) for in-vitro fertilisation (IVF). Patients were allocated to three groups to receive buserelin 150 μg nasal spray three times daily (Group B), nafarelin nasal spray 400 μg twice daily (Group N), or leuprorelin depot 3.75 mg once by intramuscular or subcutaneous injection (Group L) for pituitary desensitisation prior to commencing COH with human menopausal gonadotrophins (hMG) according to the Centre’s protocol. The mean (±S.D.) age (years) (32.6±3.8: Group B, 32.1±3.3: Group N versus 32.1±3.3: Group L); mean (±S.D.) total dosage of hMG (ampoules) (37.5±16.1: Group B, 39.8±14.2: Group N versus 41.9±12.6: Group L) and mean daily dosage of hMG (ampoules) (3.1: Group B, 2.8: Group N versus 3.0: Group L) seen were not statistically significantly different. The duration between starting the different gonadotrophin-releasing hormone (GnRHa) and the beginning of the next menstrual period was also not seen to be statistically significantly different between the three groups (Group B: 10±5.5, Group N: 9.1±4.1 versus Group L: 8.2±3, days). The number of abandoned cycles was higher in Group L (17% versus 11.8%: Group B and 11.3%: Group N) but this difference did not reach statistical significance. The clinical pregnancy rates per oocyte retrieval and per embryo transfer procedure were respectively, 31.1, 35% in Group B, 12.8, 14% in Group N versus 20.5, 23.7 in Group L and were not seen to be statistically significantly different even when ongoing pregnancy rates were compared. Apart from a statistically significantly greater incidence of allergic nasal reactions in the nafarelin group ( P=0.001), all other side-effects were not shown to be statistically significantly different between the three groups. We conclude that a single dose of leuprorelin depot can be considered to be as an equally effective alternative to multiple doses of buserelin or nafarelin for pituitary desensitisation in women undergoing COH for IVF.